The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders

被引：11

作者：

Musto, Pellegrino ^{[1
]}

D'Auria, Fiorella ^{[1
]}

机构：

[1] Ctr Riferimento Oncol Basilicata, Dept Oncohematol, IRCCS, I-85028 Rionero In Vulture, Pz, Italy

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2011年 / 11卷 / 05期

关键词：

anti-CD20 monoclonal antibodies; CD20; antigen; modulation; chronic lymphocytic leukemia; non-Hodgkin's lymphoma; Richter's syndrome; rituximab; CHRONIC LYMPHOCYTIC-LEUKEMIA; B-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; IMMUNOPHENOTYPIC CHANGES; THERAPEUTIC ACTIVITY; FOLLICULAR LYMPHOMA; DOWN-REGULATION; TUMOR-CELLS; EXPRESSION; COMPLEMENT;

D O I：

10.1517/14712598.2011.567262

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Immunotherapy using an antibody (rituximab) targeting CD20 antigen in combination with chemotherapy has been recently associated with significantly improved response rate and survival in patients with various types of CD20-positive B-cell lymphoproliferative disorders. This treatment may induce the disappearance of CD20 surface expression on neoplastic B-cells. Several mechanisms have been proposed to explain CD20 loss after rituximab therapy, while the clinical significance (if any) of this phenomenon is still not clear. We have produced a brief overview of the biological aspects of CD20 modulation after rituximab treatment and its possible clinical implications.

引用

页码：551 / 557

页数：7

共 52 条

[1] Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR) [J].

Alatrash, Gheath ;

Albitar, Maher ;

O'Brien, Susan ;

Wang, Xuemei ;

Manshouri, Taghi ;

Faderl, Stefan ;

Ferrajoli, Alessandra ;

Burger, Jan ;

Garcia-Manero, Guillermo ;

Kantarjian, Hagop M. ;

Lerner, Susan ;

Keating, Michael J. ;

Wierda, William G. .

BRITISH JOURNAL OF HAEMATOLOGY, 2010, 148 (03) :386-393

[2] CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma:: a new case report and review of the literature [J].

Alvaro-Naranjo, T ;

Jaén-Martínez, J ;

Gumá-Padró, J ;

Bosch-Príncep, R ;

Salvadó-Usach, MT .

ANNALS OF HEMATOLOGY, 2003, 82 (09) :585-588

[3] Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia [J].

Aue, Georg ;

Lindorfer, Margaret A. ;

Beum, Paul V. ;

Pawluczkowycz, Andrew W. ;

Vire, Berengere ;

Hughes, Thomas ;

Taylor, Ronald P. ;

Wiestner, Adrian .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (02) :329-332

[4] Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection [J].

Beers, Stephen A. ;

French, Ruth R. ;

Chan, H. T. Claude ;

Lim, Sean H. ;

Jarrett, Timothy C. ;

Vidal, Regina Mora ;

Wijayaweera, Sahan S. ;

Dixon, Sandra V. ;

Kim, Hyungjin ;

Cox, Kerry L. ;

Kerr, Jonathan P. ;

Johnston, David A. ;

Johnson, Peter W. M. ;

Verbeek, J. Sjef ;

Glennie, Martin J. ;

Cragg, Mark S. .

BLOOD, 2010, 115 (25) :5191-5201

[5] The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes [J].

Beum, PV ;

Kennedy, AD ;

Williams, ME ;

Lindorfer, MA ;

Taylor, RP .

JOURNAL OF IMMUNOLOGY, 2006, 176 (04) :2600-2609

[6] The epitope recognized by rituximab [J].

Binder, Mascha ;

Otto, Florian ;

Mertelsmann, Roland ;

Veelken, Hendrik ;

Trepel, Martin .

BLOOD, 2006, 108 (06) :1975-1978

[7] Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].

Cartron, G ;

Dacheux, L ;

Salles, G ;

Solal-Celigny, P ;

Bardos, P ;

Colombat, P ;

Watier, H .

BLOOD, 2002, 99 (03) :754-758

[8] Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies [J].

Cheson, Bruce D. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (21) :3525-3530

[9]

Chu PG, 2002, LEUKEMIA LYMPHOMA, V43, P2335, DOI 10.1080/1042819021000040044

[10] Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy [J].

Clarke, LE ;

Bayerl, MG ;

Ehmann, WC ;

Helm, KF .

JOURNAL OF CUTANEOUS PATHOLOGY, 2003, 30 (07) :459-462

← 1 2 3 4 5 6 →